Action APHB AMPLIPHI BIOSCIENCES CORP
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Ampliphi Biosciences Corp OTC Bulletin Board

Actions

APHB

US03211P1030

Cours en clôture OTC Bulletin Board
Autres places de cotation
- USD - Graphique intraday de Ampliphi Biosciences Corp
21/03 Armata Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
21/03 Armata Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Armata Pharmaceuticals, Inc. Announces CFO Changes
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Armata Pharmaceuticals, Inc. Announces That It Has Entered into A Credit and Security Agreement with Innoviva Strategic Opportunities Llc
Armata Pharmaceuticals, Inc. Announces Executive Changes
Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARMP
  4. Action APHB
  5. Actualités Ampliphi Biosciences Corp
  6. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT